LXEO
Price:
$4.37
Market Cap:
$343.14M
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygo...[Read more]
Industry
Biotechnology
IPO Date
2023-11-03
Stock Exchange
NASDAQ
Ticker
LXEO
According to Lexeo Therapeutics, Inc. Common Stock’s latest financial reports and current stock price. The company's current PE Ratio is -3.90. This represents a change of -27.44% compared to the average of -5.37 of the last 4 quarters.
The mean historical PE Ratio of Lexeo Therapeutics, Inc. Common Stock over the last ten years is -11.87. The current -3.90 PE Ratio has changed 3.19% with respect to the historical average. Over the past ten years (40 quarters), LXEO's PE Ratio was at its highest in in the March 2025 quarter at -0.88. The PE Ratio was at its lowest in in the December 2025 quarter at -9.06.
Average
-11.87
Median
-5.16
Minimum
-49.09
Maximum
-2.13
Discovering the peaks and valleys of Lexeo Therapeutics, Inc. Common Stock PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 150.53%
Maximum Annual PE Ratio = -2.13
Minimum Annual Increase = -89.82%
Minimum Annual PE Ratio = -49.09
| Year | PE Ratio | Change |
|---|---|---|
| 2025 | -5.33 | 150.53% |
| 2024 | -2.13 | -60.51% |
| 2023 | -5.39 | 26.21% |
| 2022 | -4.27 | -14.60% |
| 2021 | -5.00 | -89.82% |
The current PE Ratio of Lexeo Therapeutics, Inc. Common Stock (LXEO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.28
5-year avg
-4.42
10-year avg
-11.87
Lexeo Therapeutics, Inc. Common Stock’s PE Ratio is less than Kyverna Therapeutics, Inc. (-3.11), greater than Contineum Therapeutics, Inc. Class A Common Stock (-7.59), less than Silence Therapeutics plc (-3.71), less than Larimar Therapeutics, Inc. (-1.78), greater than Capricor Therapeutics, Inc. (-12.93), less than Mereo BioPharma Group plc (-1.37), less than Voyager Therapeutics, Inc. (-1.79), greater than DBV Technologies S.A. (-8.91), greater than Amarin Corporation plc (-9.43), less than Vanda Pharmaceuticals Inc. (-1.46),
| Company | PE Ratio | Market cap |
|---|---|---|
| -3.11 | $352.74M | |
| -7.59 | $444.15M | |
| -3.71 | $316.00M | |
| -1.78 | $296.96M | |
| -12.93 | $1.18B | |
| -1.37 | $48.68M | |
| -1.79 | $211.47M | |
| -8.91 | $416.60M | |
| -9.43 | $315.21M | |
| -1.46 | $353.00M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lexeo Therapeutics, Inc. Common Stock using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lexeo Therapeutics, Inc. Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Lexeo Therapeutics, Inc. Common Stock's PE Ratio?
How is the PE Ratio calculated for Lexeo Therapeutics, Inc. Common Stock (LXEO)?
What is the highest PE Ratio for Lexeo Therapeutics, Inc. Common Stock (LXEO)?
What is the 3-year average PE Ratio for Lexeo Therapeutics, Inc. Common Stock (LXEO)?
What is the 5-year average PE Ratio for Lexeo Therapeutics, Inc. Common Stock (LXEO)?
How does the current PE Ratio for Lexeo Therapeutics, Inc. Common Stock (LXEO) compare to its historical average?